SYDNEY, Feb. 7, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that it has received a confirmation from the US Food and Drug Administration (FDA) that the diagnostic ⁶⁴Cu...